Rosen Law Firm Closes Investigation And Concludes There Is No Basis For Securities Claims Against HTBX

Rosen Law Firm announces that, following discussions with management and having gained a better understanding of the facts surrounding Heat Biologic's (NASDAQ:HTBX) recent bladder cancer trial for Vesigenurtacel-L (HS-410), including the positive immunological data generated from this trial, it is closing its investigation of HTBX. Rosen attorney Phil Kim stated "We have concluded that there is no suggestion that management misrepresented the results of the clinical trial, and there is no basis for any securities claims."

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161201006419/en/
Copyright Business Wire 2010

If you liked this article you might like

These 5 Stocks Under $10 Could Get Hot Soon

These 5 Stocks Under $10 Could Get Hot Soon

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

8 Breakout Stocks Under $10 to Trade for Big Profits

8 Breakout Stocks Under $10 to Trade for Big Profits

4 Breakout Stocks Under $10 Making Big Moves

4 Breakout Stocks Under $10 Making Big Moves

3 Stocks Advancing The Drugs Industry

3 Stocks Advancing The Drugs Industry